It is an exciting time of growth for argenx as we strive to achieve our VISION 2030. Vision 2030 is our long-term commitment to transform the treatment of autoimmune diseases by strengthening our leadership in neonatal Fc receptor (FcRn) biology, investing in our continuous pipeline of differentiated antibody candidates, and scaling in a disciplined way to ensure innovation remains core to the argenx mission. ‘Vision 2030’ includes the following goals: 50,000 patients globally on treatment with an argenx medicine, 10 labeled indications across all approved assets, including VYVGART and potentially empasiprubart and ARGX-119 and five new molecules in Phase 3 development.

The Medical Science Liaison (MSL), a field-based extension of the Medical Affairs team, is an expert on argenx’s scientific data, products and trials, and is responsible for engagement with Key Opinion Leaders at academic and community centers, including potential and confirmed clinical research sites.